<DOC>
	<DOCNO>NCT01439750</DOCNO>
	<brief_summary>This phase I/II trial bortezomib , cladribine , rituximab newly diagnose relapse mantle cell lymphoma ( MCL ) . The phase I component three dose level cladribine ( 3 mg/m2 , 4 mg/m2 , 5 mg/m2 ) design traditional dose-escalation study cohort 3 patient evaluated incidence dose-liming toxicity ( DLT ) dose level . Once maximum tolerate dose ( MTD ) determine , phase II component 2 arm begin . One arm enroll newly diagnose MCL patient one arm enroll relapse MCL patient . Each arm single-stage , fix sample size study accrue analyze separately . The phase I II data also analyze separately .</brief_summary>
	<brief_title>Bortezomib ( VELCADE ) , Cladribine Rituximab ( VCR ) Mantle Cell Lymphoma ( PSHCI 10-011 )</brief_title>
	<detailed_description>The phase I portion study standard dose-escalation scheme design determine maximum tolerate dose ( MTD ) combination bortezomib , cladribine , rituximab therapy . The MTD define dose level ≤1 6 patient dose-limiting toxicity ( DLT ) . Three patient enrol dose level . If 0 3 patient DLT , next set 3 patient enrol next high dose level . If ≥2 3 patient DLT , MTD exceed dose escalation cease . Three additional patient enrol next low dose level 3 treat previously level . If 1 3 patient DLT , next set 3 patient treat dose level . If ≤1 6 patient treat dose level DLT , next set patient treat next high dose level . If ≥2 6 patient treat dose level DLT , MTD exceed dose escalation cease . Three additional patient treat next low dose level 3 treat previously level . This phase I study use 3 dose level cladribine ( 3 mg/m2 , 4 mg/m2 , 5 mg/m2 ) , 3 mg/m2 start dose level . DLTs assess completion first 2 cycle cladribine rituximab . Phase II Design : The phase II portion study two-arm , single-stage design interim analysis . One arm accrue newly diagnose patient , one arm accrue relapse patient . In arm , progression-free survival rate 2 year use primary endpoint determine whether treatment sufficiently active arm . No comparison make arm .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<criteria>Females postmenopausal least 1 year screen visit , surgically sterilize childbearing potential agree practice 2 effective method contraception time sign informed consent form 30 day last dose . Male subject must agree practice effective barrier contraception entire study treatment period minimum 30 day last dose study drug , completely abstain heterosexual intercourse . Patients newly diagnose relapse mantle cell lymphoma . ECOG performance status grade 3 high . Patient platelet count &lt; 50x10 9/L within 14 day enrollment related disease . Patient absolute neutrophil count le 100 within 14 day enrollment related disease . Patient calculate measured creatinine clearance &lt; 20 mL/minute within 14 day enrollment . Patient &gt; Grade 2 peripheral neuropathy within 14 day enrollment . Patient &gt; 1.5 x ULN total bilirubin . Myocardial infarction within 6 month prior enrollment New York Heart Association Class II IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Patient hypersensitivity bortezomib , boron mannitol . Female subject pregnant breastfeeding . Patient receive investigational drug within 14 day enrollment . Serious medical psychiatric illness likely interfere participation clinical study . Diagnosed treat another malignancy within 3 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>mantle cell lymphoma</keyword>
	<keyword>lymphoma</keyword>
</DOC>